News

HHS Secretary Robert F. Kennedy Jr. is considering a regulatory framework for Medicare and Medicaid GLP-1 coverage, but only for patients who have 'exhausted other options' — specifically glucose monitors (~$80/month), diet changes, and exercise. Verified April 2026: what Kennedy said on CBS News April 15 and at the House Ways and Means hearing April 16, how the gate would work, and how it stacks with the already-announced Medicare GLP-1 Bridge launching July 2026.

Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.

Verified April 2026: FDA removed semaglutide from shortage list Oct 2024. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo $649/mo.

Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.

Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026 — the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.

Verified April 11, 2026: 81 days until the Medicare GLP-1 Bridge launches July 1, 2026. Complete prep checklist: Part D enrollment verification, BMI documentation, comorbidity coding, prior auth prep. Free Medicare Eligibility Checker tool inside.

The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.